D
Biogen Inc. BIIB
$146.77 $3.002.09%
Recommendation
Sell
Prev Close
$143.77
Volume
443,609
Avg Vol (90D)
1,554,971
Market Cap
$21.04B
Dividend & Yield
--
52-Week Range
$128.51 - $238.00
P/E (TTM)
12.86
EPS (TTM)
$11.18
My Lists My Alerts
Rating
Reward
C
Fair
Risk
D
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Good
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Biogen Stock Is Mutating Into a Value Play
2/20/2025 - MarketBeat
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
3/6/2025 - Benzinga
Biogen Inc. (NASDAQ:BIIB) Shares Bought by Mission Wealth Management LP
3/6/2025 - Ticker Report
State of Michigan Retirement System Increases Stock Holdings in Biogen Inc. (NASDAQ:BIIB)
3/6/2025 - Ticker Report
SVB Wealth LLC Acquires New Shares in Biogen Inc. (NASDAQ:BIIB)
3/6/2025 - MarketBeat
Biogen (NASDAQ:BIIB) Stock Price Up 3.5% - Still a Buy?
3/5/2025 - MarketBeat
Seizert Capital Partners LLC Has $6.07 Million Stake in Biogen Inc. (NASDAQ:BIIB)
3/5/2025 - Ticker Report
Seizert Capital Partners LLC Has $6.07 Million Stake in Biogen Inc. (NASDAQ:BIIB)
3/5/2025 - MarketBeat
What the Options Market Tells Us About Biogen
3/4/2025 - Benzinga
Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)
3/3/2025 - SeekingAlpha
Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)
3/3/2025 - Seeking Alpha: Transcripts
Quintet Private Bank Europe S.A. Purchases 705 Shares of Biogen Inc. (NASDAQ:BIIB)
3/3/2025 - Ticker Report
Eisai, Biogen announce TGA of Australia declined approval of lecanemab
3/3/2025 - TipRanks Financial Blog
Eisai, Biogen announce TGA of Australia declined approval of lecanemab
3/3/2025 - The Fly
Biogen Inc. (NASDAQ:BIIB) Shares Sold by National Pension Service
3/1/2025 - MarketBeat
Bank of New York Mellon Corp Has $149.07 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB)
3/1/2025 - MarketBeat
Private Advisor Group LLC Cuts Position in Biogen Inc. (NASDAQ:BIIB)
3/1/2025 - MarketBeat
Biogen (NasdaqGS:BIIB) Awaits EU Decision On Lecanemab After CHMP Reaffirms Positive Opinion
2/28/2025 - Simply Wall St
Biogen, Eisai Alzheimer's drug sent back for EU nod after safety review
2/28/2025 - Seeking Alpha - Healthcare
Biogen Inc (BIIB) and Eisai's Lecanemab Receives Positive Reaffirmation from European Medicines ...
2/28/2025 - GuruFocus
Biogen, Eisai confirm CHMP positive opinion for lecanemab
2/28/2025 - The Fly
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
2/28/2025 - PR Newswire
Biogen, Eisai announces CHMP of EMA reaffirmed positive opinion of lecanemab
2/28/2025 - TipRanks Financial Blog
Biogen, Eisai announces CHMP of EMA reaffirmed positive opinion of lecanemab
2/28/2025 - The Fly
2,819 Shares in Biogen Inc. (NASDAQ:BIIB) Purchased by Advisor OS LLC
2/28/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$9.68B
EBITDA (TTM)
$3.14B
EBIT (TTM)
$2.47B
Net Income (TTM)
$1.63B
Balance Sheet
Total Assets (Q)
$28.05B
Total Debt (Q)
$6.72B
Total Liabilities (Q)
$11.33B
Book Value Per Share (Q)
$114.65
Cash Flow
Cash from Operations (TTM)
$2.88B
Cash from Investing (TTM)
-$799.20M
Cash from Financing (TTM)
-$683.50M
Net Change in Cash (TTM)
$1.33B
Filings
Filing Date
Wednesday, February 12, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Apr 21 and 25 (est)
Price History
Loading...
Beta
0.71
7-Day Total Return
2.28%
30-Day Total Return
2.79%
60-Day Total Return
-7.87%
90-Day Total Return
-19.81%
Year to Date Total Return
-2.18%
1-Year Total Return
-32.56%
2-Year Total Return
-45.71%
3-Year Total Return
-28.70%
5-Year Total Return
-53.85%
52-week Low
Feb 12, 2025 - $128.51
52-week High
Jul 12, 2024 - $238.00
Valuation
Market Cap
$21.04B - Large Cap
Enterprise Value
$25.39B
Price/Sales (TTM)
2.17
Price/Book (Q)
1.25
Dividends and Shares
Shares Outstanding
146.10M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.biogen.com
Phone Number
(617) 679-2000
Address
225 Binney Street
Cambridge, MA 02142
Country
United States
Year Founded
1978
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally... more
NASDAQ 03/06/2025 2:42PM Eastern Quotes delayed
Weiss Ratings